Scientists test dual attack on stubborn blood cancer
NCT ID NCT05627232
Summary
This early-stage study is testing two new drug combinations for adults whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The first part combines tazemetostat with a standard chemotherapy drug (CPX-351). The second part tests a drug called palbociclib given before CPX-351. The main goal is to find safe doses and see if these approaches show early signs of helping control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.